Mesothelioma Effects

Press Release
Rosetta Genomics Ltd. Posted on:26 May 10 Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces new data from two studies using the Company’s miRviewâ„¢ mets test to predict the tissue of origin (ToO) in patients with cancer of unknown primary site (CUP) will be presented in a poster session and in the abstract book at …